It is the protein targeted by alemtuzumab, a monoclonal antibody used for the treatment of chronic lymphocytic leukemia. A phase III trial into treatment of relapsing-remitting multiple sclerosis showed a reduction in relapse rate, but no statistically significant reduction in accumulated disability, when used as a first-line therapy.
Alemtuzumab, a monoclonal antibody for chronic lymphocytic leukemia, targets the protein. In a phase III trial on relapsing-remitting multiple sclerosis treatment, it showed a reduced rate of relapse but no statistically significant reduction in disability accumulation when used as first-line therapy.